GXD-Bio v Myriad International (CFI, 26 November 2024)
| Date | 26 November 2024 |
|---|---|
| Court | CFI |
| Division | Munich (DE) Local Division |
| Type of action | Generic application |
| Registry reference | App_59539/2024 · ORD_59602/2024 |
| Parties | Myriad Service GmbH, Myriad Genetics, Inc., Myriad International GmbH, Myriad Genetics B.V., Eurobio Scientific, Myriad Genetics S.r.l., My… |
Official decision (PDF) · UPC registry entry
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
By order of 26 November 2024 (UPC_CFI_437/2024, ACT_43382/2024, ORD_59602/2024), the judge-rapporteur of the Munich Local Division (U. Voß), in GXD-Bio Corporation’s infringement action on EP 3 346 403 against Myriad International GmbH and eight other defendants, ordered the claimant to provide security of EUR 112,000 for the defendants’ costs by 15 January 2025, but declined to make a decision by default in advance.
Question
Should security for costs be ordered against a recently incorporated Korean patent monetisation company, and can a default decision be made in advance in case security is not provided?
Decision
The court has discretion, taking into account in particular the claimant’s financial position and the risk that a costs order may not be recoverable or enforceable. The requesting party must give reasons and the other side must contest them with substance. As the defendants’ financial information was undisputed, the risk of non-recovery was real, and the claimant did not argue that security would impair its right to an effective remedy. The choice between deposit and bank guarantee was left open, and the period of about seven weeks took account of the holidays. The request for a default decision was premature, as no time limit had yet been set. The claimant was merely warned of the risk under Rule 355. Leave to appeal was granted to the defendants.
Key points for practice
- Practical point: a decision by default can only be sought once the period for providing security has expired, not in the security application itself.
Provisions applied
- Agreement on a Unified Patent Court
- Arts. 69(4) and 73(2)(b)(ii)
- Rules of Procedure
- Rules 158.1, 220.2 and 355
- Case law cited
- Court of Appeal, 17 September 2024 (UPC_CoA_218/2024), Edwards Lifesciences v Meril, Munich Local Division, 29 September 2023, President and Fellows of Harvard College v NanoString, Munich Central Division, 30 October 2023, AIM Sport Vision v Supponor, Helsinki Local Division, 20 October 2023
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Going further
Lexicon: Written procedure (UPC), Court fees and costs (UPC).
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Proceedings
Parties
- claimantMyriad Genetics S.r.l.2 decisions in the corpusFollow this party
- claimantMyriad Genetics B.V.2 decisions in the corpusFollow this party
- claimantMyriad Genetics, Inc.2 decisions in the corpusFollow this party
- claimantMyriad Service GmbHFollow this party
- claimantMyriad International GmbHFollow this party
- claimantEurobio ScientificFollow this party
- claimantMyFollow this party
Decisions in the same proceedings and documented appeals
What the record states
- Nature of the act
- Generic application
- Outcome (Dhenne Avocats summary)
- GXD-Bio doit constituer une garantie de 112 000 euros pour les frais des défenderesses avant le 15 janvier 2025, la demande de décision par défaut anticipée est rejetée comme prématurée.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Patents mentioned
EP 3 346 403mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- NanoString Technologies Europe v President and Fellows of Harvard College (CFI, 30 October 2023) cited in this record
- AIM Sport Vision v Supponor (CFI, 20 October 2023) cited in this record
- Edwards Lifesciences v Meril (CFI, 29 September 2023) cited in this record
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 3 346 403 | Mentioned in the analysis (role not qualified) Also mentioned in 2 other decision(s): GXD-Bio v Myriad International (CFI, UPC_CFI_437/2024, 19 December 202 · GXD-Bio v Myriad Genetics (CFI, 14 February 2025) | not recorded | not recorded | not recorded | Espacenet links not checked mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.